BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922

被引:11
作者
Wang, Chun Yan [1 ]
Guo, Su Tang [1 ]
Croft, Amanda [1 ]
Yan, Xu Guang [1 ]
Jin, Lei [2 ]
Zhang, Xu Dong [1 ]
Jiang, Chen Chen [2 ]
机构
[1] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia
[2] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia
关键词
AUY922; BAG3; colon cancer; heat shock protein 90; Mcl-1; HUMAN-MELANOMA CELLS; UNFOLDED PROTEIN RESPONSE; SMALL-MOLECULE INHIBITOR; ACQUIRED-RESISTANCE; ENDOPLASMIC-RETICULUM; PROMOTES SURVIVAL; CHAPERONE COMPLEX; COLORECTAL-CANCER; DEGRADATION; THERAPY;
D O I
10.1002/mc.22755
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Past studies have shown that mutant KRAS colon cancer cells are susceptible to apoptosis induced by the HSP90 inhibitor AUY922. Nevertheless, intrinsic and acquired resistance remains an obstacle for the potential application of the inhibitor in the treatment of the disease. Here we report that Mcl-1 is important for survival of colon cancer cells in the presence of AUY922. Mcl-1 was upregulated in mutant KRAS colon cancer cells selected for resistance to AUY922-induced apoptosis. This was due to its increased stability mediated by Bcl-2-associated athanogene domain 3 (BAG3), which was also increased in resistant colon cancer cells by heat shock factor 1 (HSF1) as a result of chronic endoplasmic reticulum (ER) stress. Functional investigations demonstrated that inhibition of Mcl-1, BAG3, or HSF1 triggered apoptosis in resistant colon cancer cells, and rendered AUY922-naive colon cancer cells more sensitive to the inhibitor. Together, these results identify that the HSF1-BAG3-Mcl-1 signal axis is critical for protection of mutant KRAS colon cancer cells from AUY922-induced apoptosis, with potential implications for targeting HSF1/BAG3/Mcl-1 to improve the efficacy of AUY922 in the treatment of colon cancer.
引用
收藏
页码:284 / 294
页数:11
相关论文
共 45 条
  • [1] A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
    Abulwerdi, Fardokht
    Liao, Chenzhong
    Liu, Meilan
    Azmi, Asfar S.
    Aboukameel, Amro
    Mady, Ahmed S. A.
    Gulappa, Thippeswamy
    Cierpicki, Tomasz
    Owens, Scott
    Zhang, Tao
    Sun, Duxin
    Stuckey, Jeanne A.
    Mohammad, Ramzi M.
    Nikolovska-Coleska, Zaneta
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (03) : 565 - 575
  • [2] Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
    Azoitei, Ninel
    Hoffmann, Christopher M.
    Ellegast, Jana M.
    Ball, Claudia R.
    Obermayer, Kerstin
    Goessele, Ulrike
    Koch, Britta
    Faber, Katrin
    Genze, Felicitas
    Schrader, Mark
    Kestler, Hans A.
    Doehner, Hartmut
    Chiosis, Gabriela
    Glimm, Hanno
    Froehling, Stefan
    Scholl, Claudia
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2012, 209 (04) : 697 - 711
  • [3] Small molecule Mcl-1 inhibitors for the treatment of cancer
    Belmar, Johannes
    Fesik, Stephen W.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2015, 145 : 76 - 84
  • [4] The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737
    Boiani, Mariana
    Daniel, Cristina
    Liu, Xueyuan
    Hogarty, Michael D.
    Marnett, Lawrence J.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (10) : 6980 - 6990
  • [5] Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO
  • [6] 2-0
  • [7] Resistance to HSP90 inhibition involving loss of MCL1 addiction
    Busacca, S.
    Law, E. W. P.
    Powley, I. R.
    Proia, D. A.
    Sequeira, M.
    Le Quesne, J.
    Klabatsa, A.
    Edwards, J. M.
    Matchett, K. B.
    Luo, J. L.
    Pringle, J. H.
    El-Tanani, M.
    MacFarlane, M.
    Fennell, D. A.
    [J]. ONCOGENE, 2016, 35 (12) : 1483 - 1492
  • [8] Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90
    Bussenius, Joerg
    Blazey, Charles M.
    Aay, Naing
    Anand, Neel K.
    Arcalas, Arlyn
    Baik, TaeGon
    Bowles, Owen J.
    Buhr, Chris A.
    Costanzo, Simona
    Curtis, Jeffrey K.
    DeFina, Steven C.
    Dubenko, Larisa
    Heuer, Timothy S.
    Huang, Ping
    Jaeger, Christopher
    Joshi, Anagha
    Kennedy, Abigail R.
    Kim, Angie I.
    Lara, Katherine
    Lee, Jae
    Li, Jonathan
    Lougheed, Julie C.
    Ma, Sunghoon
    Malek, Shiva
    Manalo, Jean-Claire L.
    Martini, Jean-Francois
    McGrath, Garth
    Nicoll, Monique
    Nuss, John M.
    Pack, Michael
    Peto, Csaba J.
    Tsang, Tsze H.
    Wang, Longcheng
    Womble, Scott W.
    Yakes, Michael
    Zhang, Wentao
    Rice, Kenneth D.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (17) : 5396 - 5404
  • [9] Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer
    Cercek, Andrea
    Shia, Jinru
    Gollub, Marc
    Chou, Joanne F.
    Capanu, Marinela
    Raasch, Pamela
    Reidy-Lagunes, Diane
    Proia, David A.
    Vakiani, Efsevia
    Solit, David B.
    Saltz, Leonard B.
    [J]. CLINICAL COLORECTAL CANCER, 2014, 13 (04) : 207 - 212
  • [10] Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors
    Chai, Ryan C.
    Vieusseux, Jessica L.
    Lang, Benjamin J.
    Nguyen, Chau H.
    Kouspou, Michelle M.
    Britt, Kara L.
    Price, John T.
    [J]. MOLECULAR ONCOLOGY, 2017, 11 (05): : 567 - 583